Contraceptive Drug Eluting Device Global Market Insights 2025, Analysis and Forecast to 2030, by Manufacturers, Regions, Technology, Application, Product Type

Contraceptive Drug Eluting Device Market 2025 Review

Overview

The contraceptive drug eluting device market is witnessing significant advancements driven by growing awareness of family planning and reproductive health. These innovative devices provide effective contraception through the controlled release of hormones, offering women a long-term solution for family planning. With a focus on comfort, safety, and efficacy, the market is poised for substantial growth in the coming years.

Market Size

The global contraceptive drug eluting device market was valued at approximately $3.8 billion in 2025 and is projected to reach around $6.9 billion by 2030, growing at a CAGR of about 10.4% from 2025 to 2030. This growth can be attributed to increasing demand for advanced contraceptive solutions and rising awareness about reproductive health.

Market Share & Trends Analysis

By Product Type

The market is segmented into non-biodegradable and biodegradable drug eluting devices. As of 2025:

• Non-biodegradable devices: Expected to hold over 65% of the market share due to their reliability and long-term effectiveness.
• Biodegradable devices: Anticipated to grow with a CAGR of 12% due to increasing preferences for eco-friendly solutions.

Key Players

Major companies operating in the contraceptive drug eluting device market include:

• Bayer
• AbbVie
• CooperSurgical
• Egemen International
• ERENLER MEDIKAL
• Gyneas
• Laboratoire CCD
• Medical Engineering Corporation
• Melbea
• Meril Life Sciences
• Mona Lisa
• Pregna International
• Prosan International
• Rongbo Medical
• SMB Corporation of India

These companies are focusing on product innovation and strategic collaborations to enhance their market presence.

By Process

The market is categorized based on the process of drug elution, including:

• Subcutaneous: This segment is growing rapidly, accounting for approximately 40% of the market share.
• Uterus: Representing around 60% of the market, this segment is expected to witness robust growth driven by the demand for intrauterine contraceptive devices (IUDs).

By Application

Contraceptive drug eluting devices find applications in various medical fields, primarily:

• Subcutaneously
• Intrauterine

By End-Use

The end-use segments include hospitals, clinics, and home care settings. Currently, clinics dominate the market, contributing to over 50% of the total share, driven by the rising number of healthcare facilities addressing family planning.

By Region

The key regions analyzed in the contraceptive drug eluting device market include:

• North America: The largest market, projected to grow at a CAGR of 9% due to advanced healthcare infrastructure and increasing awareness.
• Europe: Also a significant region, with a market share of about 25%, driven by the proliferation of reproductive health programs.
• Asia-Pacific: Expected to experience the fastest growth rate of 11% through 2030, fueled by increasing urbanization and service accessibility.
• Latin America and Middle East & Africa: Contributing to the market, though at a slower growth pace, influenced by varying levels of healthcare access.

Market News on Policy and Companies

Recent changes in reproductive health policies and increased funding toward family planning initiatives are boosting the demand for contraceptive drug eluting devices globally. Companies are also investing heavily in R&D to develop next-generation devices that are more effective and user-friendly.

Key players are focusing on mergers and acquisitions to strengthen their product portfolios. For instance, Bayers acquisition of Mercks over-the-counter business has expanded its reach in the contraceptive market. Meanwhile, AbbVie is investing in the development of new delivery systems to enhance hormonal contraception efficacy.

Segment Forecasts, 2025 - 2030

Based on projections, the contraceptive drug eluting device market is expected to continue its upward trajectory, supported by:

• Increased awareness and accessibility of contraceptive methods.
• Technological advancements leading to more effective and less invasive devices.
• Expansion of healthcare infrastructures, particularly in developing regions.

In summary, the contraceptive drug eluting device market is set for substantial growth from 2025 to 2030, characterized by key trends in product development, regional expansion, and evolving healthcare policies aimed at improving reproductive health worldwide.